Heroin produced antinociception in the tail flick test through μ receptors in the brain of ICR and CD-1 mice, a response inhibited by 3-O-methylnaltrexone. Tolerance to morphine was produced by subcutaneous morphine pellet implantation. By the third day, the heroin response was produced through δ opioid receptors. The response was inhibited by simultaneous intracerebroventricular (i.c.v.) administration of naltrindole, a δ opioid receptor antagonist. More specifically, δ1 rather than δ2 receptors were involved because 7-benzylidenenaltrexone, a δ1 receptor antagonist, inhibited but naltriben, a δ2 antagonist, did not. Also, antinociception produced by i.c.v. heroin was inhibited by intrathecal administration of bicuculline and Picrotoxin consistent with the concept that δ1 receptors in the brain mediated the antinociceptive response through descending neuronal pathways to the spinal cord to activate GABAA and GABAB receptors rather than spinal α2-adrenergic and serotonergic receptors activated originally by the μ agonist action in naive mice. The μ response of 6-monoacetylmorphine, a metabolite of heroin, was changed by morphine pellet implantation to a δ2 response (inhibited by naltriben but not 7-benzylidenenaltrexone). The agonist action of morphine in these morphine-tolerant mice remained μ. Thus, the opioid receptor selectivity of heroin and 6-monoacetylmorphine in the brain is changed by production of tolerance to morphine. Such a change explains how morphine tolerant mice are not cross-tolerant to heroin.
WayEL, YoungJM, KempJW. Metabolism of heroin and its pharmacologic implications. Bull Narc17: 25–33, 1965.
3.
InturrisiCE, MaxMB, FoleyKM, SchultzM, ShinS-U, HoudeRW. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med310: 1213–1217, 1984.
4.
OldendorfWM, HymanS, BraunL, OldendorfSZ. Blood-brain barrier: Penetration of morphine, codeine, heroin, and methadone after carotid injection. Science178: 984–986, 1972.
5.
MartinWR, FrazerHF. A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts. J Pharmacol Exp Ther133: 388–399, 1961.
6.
InturrisiCE, SchultzM, ShinS, UmansJG, AngelL, SimonEJ. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci3: 773–776, 1983.
7.
RadyJJ, ElmerGI, FujimotoJM. Opioid receptor selectivity of heroin given intracerebroventricularly differs in six strains of inbred mice. J Pharmacol Exp Ther288: 438–445, 1999.
8.
RadyJJ, RoerigSC, FujimotoJM. Heroin acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception. J Pharmacol Exp Ther256: 448–457, 1991.
9.
RadyJJ, AksuF, FujimotoJM. The heroin metabolite, 6-monoacetylmorphine, activates δ opioid receptors to produce antinociception in Swiss Webster mice. J Pharmacol Exp Ther266: 1222–1231, 1994.
10.
RadyJJ, GornyJ, FujimotoJM. Heroin antinociception changed from μ to δ receptor in streptozotocin-treated mice. Jpn J Pharmacol78: 443–454, 1998.
11.
LangeDG, RoerigSC, FujimotoJM, WangRIH. Absence of cross-tolerance to heroin in morphine-tolerant mice. Science208: 72–74, 1980.
12.
HolmesBB, FujimotoJM. [D-Pen2-D-Pen5]enkephalin, a δ opioid agonist, given intracerebroventricularly in the mouse produces antinociception through mediation of spinal GABA receptors. Pharmacol Biochem Behav49: 675–682, 1994.
D'AmourFE, SmithDL. A method for determining loss of pain sensation. J Pharmacol Exp Ther72: 74–79, 1941.
16.
DeweyWL, HarrisLS, HowesJF, NuiteJA. The effect of various neurohormonal modulators on the activity of morphine and the narcotic antagonists in the tail flick and phenylquinone test. J Pharmacol Exp Ther175: 435–442, 1970.
SteelRGD, TorrieJH. Principles and Procedures of Statistics with Special Reference to the Biological Sciences. New York: McGraw-Hill Book Company, Inc., pp 99–111, 1960.
25.
PortoghesePS, SultanaM, NagaseH, TakemoriAE. Application of the message-address concept in the design of highly potent and selective non-peptide δ opioid antagonists. J Med Chem31: 281–282, 1988.
WigdorS, WilcoxGL. Central and systemic morphine-induced antinociception in mice: Contribution of descending serotonergic and noradrenergic pathways. J Pharmacol Exp Ther242: 90–95, 1987.
28.
ArtsKS, HolmesBB, FujimotoJM. Morphine and D-Ala-N-methyl-Phe-Gly-ol activates descending noradrenergic and serotonergic antinociceptive systems to different degrees. J Pharmacol Exp Ther257: 890–896, 1991.
29.
PickCG, PaulD, PasternakGW. Comparison of naloxonazine and β-funaltrexamine antagonism of μ1 and μ2 opioid actions. Life Sci48: 2005–2011, 1991.
30.
PickCG, NejatRJ, PasternakGW. Independent expression of two pharmacologically distinct supraspinal μ analgesic systems in genetically different mouse strains. J Pharmacol Exp Ther265: 166–171, 1993.
31.
ZakiPA, BilskyEJ, EvansCJ, PorrecaF.Opioid receptor types and subtypes: The δ receptors as a model. Annu Rev Pharmacol Toxicol36: 379–401, 1996.
32.
RoerigSC, FujimotoJM. Morphine antinociception in different strains of mice: Relationship of supraspinal-spinal multiplicative interaction to tolerance. J Pharmacol Exp Ther247: 603–608, 1988.
33.
SimonGS, DeweyWL. Narcotics and diabetes. I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J Pharmacol Exp Ther218: 318–323, 1991.
34.
KameiJ, IwamotoY, HitosugiH, MisawaM, NagaseH, KasuyaY.Streptozotocin-induced diabetes selectively reduces antinociception mediated by μ1-opioid receptors, but not that mediated by μ2-opioid receptors. Neurosci Lett165: 141–143, 1994.
35.
KameiJ, IwamotoY, MisawaM, NagaseH, KasuyaY.Streptozotocin-induced diabetes selectively enhances antinociception mediated by δ1- but not δ 2-opioid receptors. Life Sci55: 121–126, 1994.
36.
HolmesBB, RadyJJ, FujimotoJM. Heroin acts on δ opioid receptors in the brain of streptozotocin-induced diabetic rats. Proc Soc Exp Biol Med218: 334–340, 1998.
37.
DanksJA, TortellaFC, LongJB, BykovV, JacobsonAE, RiceKC. Chronic administration of morphine and naltrexone upregulate[3H][D-Ala2,d-leu5]enkephalin binding sites by different mechanisms. Neuropharmacology27: 965–974, 1988.
38.
HoladayJ.Upregulation of the μ-noncompetitive δ binding site by chronic morphine administration: Effect of preincubating membranes in 400 nM sodium chloride. NIDA Res Monogr75: 93–96, 1986.
RothmanRB, LongJB, BykovV, XuH, JacobsonAE, RiceKC, HoladayJW. Upregulation of the opioid receptor complex by the chronic administration of morphine: A biochemical marker related to the development of tolerance and dependence. Peptides12: 151–160, 1991.
41.
YukhanovRY, KlodtPM, Il'inaD, ZaitsevSV, MaiskyAI. Opiate withdrawal intensity correlated with presence of DSLET high-affinity binding. Pharmacol Biochem Behav49: 1109–1112, 1994.
42.
TakemoriAE, PortoghesePS. Evidence for the interaction of morphine with κ and δ opioid receptors to induce analgesia in β-funaltrexamine-treated mice. J Pharmacol Exp Ther243: 91–97, 1987.
PaktorJ, VaughtJL. Differential analgesic cross-tolerance to morphine between lipophilic and hydrophilic narcotic agonists. Life Sci34: 13–21, 1983.
45.
PatrickGA, DeweyWL, SpauldingTC, HarrisLS. Relationship of brain morphine levels to analgesic activity in acutely treated mice and rats and in pellet implanted mice. J Pharmacol Exp Ther193: 876–883, 1975.
46.
SofuogluM, PortoghesePS, TakemoriAE. Differential antagonism of δ opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: Evidence for δ opioid receptor subtypes. J Pharmacol Exp Ther257: 676–680, 1991.
47.
LangeDG, RoerigSC, FujimotoJF, WangRI. Enhancement of etorphine brain concentrations and changes in etorphine-naloxone pA2 values in morphine-pretreated mice. Biochem Pharmacol30: 147–155, 1981.
48.
TulunayFC, TakemoriAE. The increased efficacy of narcotic antagonists induced by various narcotic analgesics. J Pharmacol Exp Ther190: 395–400, 1974.
